# A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

> **NCT05438706** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 70 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** chidamide
- **DRUG:** camrelizumab
- **DRUG:** carboplatin
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT05438706
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-10
- **Primary completion:** 2023-11-10
- **Final completion:** 2024-07-10
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438706, "A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05438706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*